Tasly Pharmaceutical Faces Long-Term Growth Challenges Amid Recent Valuation Adjustments

Tasly Pharmaceutical Group Co., Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. The company's valuation score has been revised, reflecting a shift in its financial metrics. Notably, the P/E ratio stands at 22, while the Price to Book Value is recorded at 1.64. The EV to EBIT ratio is noted at 14.41, and the EV to EBITDA is at 11.46, indicating a comprehensive assessment of its financial standing. Despite these metrics, the company has faced challenges in long-term growth, with net sales declining at an annual rate of -9.48% and operating profit decreasing by -2.22% over the past five years. Recent financial results have also shown a decline, with operating cash flow reaching its lowest at CNY 912.93 million and net profit falling by -55.59% in the last quarter. Additionally, the dividend payout ratio has hit a low of 0%. Overall, while Tasly Pharmaceutical Group Co., Ltd. has seen some positive financial performance in the latest quarter, the long-term outlook remains complex, marked by underperformance relative to broader market indices. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.